Biomarin is still expecting an EMA decision on hemophilia drug in H1 2022

The international pharmaceutical giant Biomarin is anticipating a decision in the first half of 2022 from the EMA about its candidate, Valoctocogene, meant to treat severe hemophilia. More information about the ongoing phase III trial with the drug will come in the New Year, says CEO.

Biomarin hopes to have a European approval of its potential new drug for the treatment of severe hemophilia A before summer 2022, the company reports in a press release in connection with its third quarter results.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs